Given the AMBAR trial has shown cognitive benefits for TPE with albumin treated AD patients [15], we expect wider utilization of this promising therapeutic approach, and opportunities to assess TPE clearance of EVs implicated in AD pathogenesis. Here, ALB is linked to Alzheimer disease.